Arbutus Biopharma (NASDAQ:ABUS) Rating Reiterated by Chardan Capital

Chardan Capital reiterated their buy rating on shares of Arbutus Biopharma (NASDAQ:ABUS - Free Report) in a report published on Wednesday, Benzinga reports. The firm currently has a $4.00 price objective on the biopharmaceutical company's stock.

A number of other research analysts have also recently commented on the stock. JMP Securities reissued a market outperform rating and issued a $4.00 target price on shares of Arbutus Biopharma in a report on Thursday, April 4th. HC Wainwright dropped their price objective on shares of Arbutus Biopharma from $6.00 to $5.00 and set a buy rating for the company in a report on Friday, March 1st.

Arbutus Biopharma Stock Performance

Shares of ABUS stock traded up $0.29 on Wednesday, hitting $3.63. The company's stock had a trading volume of 2,082,405 shares, compared to its average volume of 1,157,338. Arbutus Biopharma has a fifty-two week low of $1.69 and a fifty-two week high of $3.63. The stock's 50 day moving average is $2.95 and its 200-day moving average is $2.62. The company has a market capitalization of $685.05 million, a PE ratio of -8.25 and a beta of 1.98.

Arbutus Biopharma (NASDAQ:ABUS - Get Free Report) last posted its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, hitting the consensus estimate of ($0.10). The business had revenue of $1.53 million during the quarter, compared to analysts' expectations of $2.16 million. Arbutus Biopharma had a negative net margin of 572.81% and a negative return on equity of 62.68%. On average, research analysts forecast that Arbutus Biopharma will post -0.39 earnings per share for the current year.

Institutional Trading of Arbutus Biopharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Walleye Trading LLC acquired a new stake in Arbutus Biopharma during the 1st quarter valued at approximately $36,000. PFG Investments LLC acquired a new stake in shares of Arbutus Biopharma during the 1st quarter worth approximately $50,000. China Universal Asset Management Co. Ltd. grew its position in shares of Arbutus Biopharma by 351.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 19,400 shares of the biopharmaceutical company's stock worth $49,000 after buying an additional 15,104 shares during the period. Premier Path Wealth Partners LLC acquired a new stake in shares of Arbutus Biopharma during the 4th quarter worth approximately $56,000. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Arbutus Biopharma by 22.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 36,388 shares of the biopharmaceutical company's stock worth $94,000 after buying an additional 6,649 shares during the period. Institutional investors and hedge funds own 43.79% of the company's stock.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.